Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing the data from two recent presentations on HNSCC from ASCO 2023: PDS Biotech's PDS0101 and Bicara Therapeutics' BCA101.

Ticker(s): PDSB, Bicara Therapeutics

Who's the expert?

Institution: UNC School of Medicine / Novant Health Cancer Institute

Clinical Assistant Professor of Medicine of Hematology and Oncology at UNC School of Medicine
Clinical interest in Head, Neck, and Thoracic oncology, as well as disparities in cancer outcomes.
Research interest in lung cancer, earning a merit award from the American Society of Clinical Oncology in 2012

Interview Goal

On this call we will be digging in to the data presented at ASCO for PDS Biotech's, PDS0101 (targeted immunotherapy for HPV-positive HNSCC) and Bicara Therapeutics' BCA101 (bifunctional EGFR/TGF-β antibody in HPV-negative patients).

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.